Connecting the Dots- Hereditary Alpha-Tryptasemia(HaT) and MTHFR Mutation in a Diagnostic Puzzle

Background: Hereditary alpha-tryptasemia (HaT) is an autosomal dominant genetic trait caused by duplication or triplication of the TPSAB1 gene encoding α-tryptase, resulting in elevated basal serum tryptase levels and variable multisystem manifestations. Symptoms often include gastrointestinal disturbances, autonomic dysfunction, flushing, urticaria, musculoskeletal complaints, and neuropsychiatric features. The methylenetetrahydrofolate reductase (MTHFR) C677T variant is a common polymorphism associated with impaired folate metabolism, hyperhomocysteinemia, and altered methylation capacity, occasionally implicated in neuropsychiatric and cardiovascular symptoms. The pediatric phenotype of HaT remains undercharacterized, and the coexistence of HaT and MTHFR variants has not been previously documented.

Case Presentation Summary: We report a 12-year-old boy with high-functioning autism and ADHD who presented with multisystem symptoms including abdominal pain, alternating bowel habits, headaches, dizziness, intermittent urticaria, angioedema, cough, shortness of breath, lower-limb pain, and postural orthostatic tachycardia syndrome (POTS). He also demonstrated heightened anxiety and attention difficulties. Physical examination and conventional laboratory work-up were unremarkable, except for an elevated basal serum tryptase (20 ng/mL). Abdominal ultrasound was normal; bone marrow biopsy and KIT D816V mutation testing excluded systemic mastocytosis. Digital PCR confirmed two additional TPSAB1 gene copies (genotype 4a-2b), establishing hereditary alpha-tryptasemia. Extended genetic analysis revealed an MTHFR C677T variant. Both parents were carriers of extra TPSAB1 alleles, consistent with autosomal-dominant inheritance. The child's symptoms improved markedly with the H1-antihistamine bilastine.

Learning Points: This case illustrates the challenge of differentiating HaT from mast cell activation syndromes and other systemic disorders in pediatric patients. High BST in the presence of systemic symptoms warrants TPSAB1 copy-number analysis, particularly when bone marrow and KIT results are negative.

Potential gene–gene interaction: The co-occurrence of HaT and MTHFR C677T suggests a possible mechanistic interplay. Reduced methylation capacity in MTHFR deficiency may impair regulation of mast cell-related genes or histamine degradation pathways (via HNMT), amplifying HaT-related mediator effects such as flushing, dysautonomia, and neurocognitive symptoms.

Clinical implications: Both mast cell activation and autonomic dysfunction may contribute synergistically to symptom burden. Elevated homocysteine in MTHFR variants may further impact vascular tone and neuronal function.

Management: There is no disease-modifying therapy for HaT. Symptom-guided treatment includes H1/H2 antihistamines, leukotriene blockers, and mast cell stabilizers such as cromolyn. Monitoring folate, vitamin B12, and homocysteine levels is advisable in patients with MTHFR variants to optimize methylation balance.

Future directions: This is, to our knowledge, the first reported pediatric case associating HaT with an MTHFR polymorphism. It underscores the need for broader genetic and biochemical investigations in children with otherwise unexplained multisystem symptoms and elevated basal tryptase. Prospective studies should examine whether combined genetic alterations exacerbate clinical severity through interconnected methylation and mast cell pathways.